← Browse by Condition Medical Condition
metabolic dysfunction associated steatohepatitis
Trial Phases
Phase 2, Phase 3
Hepatitis clinical trials address viral hepatitis (B and C), alcoholic hepatitis, and autoimmune hepatitis — distinct conditions with different mechanisms and treatment approaches. Hepatitis C has been effectively cured in clinical trial populations since 2013 with direct-acting antiviral (DAA) regimens achieving >95% cure rates, and current trials focus on the remaining hard-to-treat groups: genotype 3 with cirrhosis, treatment-experienced patients, and real-world implementation. Hepatitis B research is now centered on achieving functional cure — sustained viral suppression after finite treatment — rather than indefinite suppression.
Active trials investigate capsid assembly modulators (CAMs), RNA interference agents (JNJ-73763989, AB-729), immune modulators (toll-like receptor agonists, PD-1 checkpoint therapy) for HBV functional cure, next-generation DAA combinations for remaining HCV challenges, and corticosteroid-sparing regimens for autoimmune hepatitis. Hepatitis D (delta) trials are notably active following the approval of bulevirtide in Europe.
HBV trials require quantitative HBsAg and HBV DNA levels at baseline; HCV trials confirm genotype and prior treatment history; autoimmune hepatitis trials require liver biopsy and elevated IgG.
Frequently Asked Questions — metabolic dysfunction associated steatohepatitis Clinical Trials
How many clinical trials are currently recruiting for metabolic dysfunction associated steatohepatitis?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for metabolic dysfunction associated steatohepatitis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for metabolic dysfunction associated steatohepatitis?
metabolic dysfunction associated steatohepatitis research spans Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a metabolic dysfunction associated steatohepatitis clinical trial?
Eligibility criteria for metabolic dysfunction associated steatohepatitis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Eccogene 1 trial
Boehringer Ingelheim 1 trial
IRCCS Azienda Ospedaliero-Universitaria di Bologna 1 trial
Recruiting Clinical Trials
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional.
Full Disclaimer ·
Last Reviewed: April 2026 ·
Data Methodology